{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:26:21Z","timestamp":1793330781226,"version":"4.5.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T00:00:00Z","timestamp":1604275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T00:00:00Z","timestamp":1604275200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background and aim<\/jats:title>\n                <jats:p>High dose brachytherapy using a non\u00a0sealed <jats:sup>188<\/jats:sup>Re-resin (Rhenium-SCT\u00ae, Oncobeta\u00ae GmbH, Munich, Germany) is a treatment option for non-melanoma skin cancer (NMSC). The aim of this prospective study was to assess the efficacy and the safety of a single application of Rhenium-SCT\u00ae in NMSC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Materials and method<\/jats:title>\n                <jats:p>Fifty consecutive patients (15F, 35\u00a0M, range of age 56\u201397, mean 81) showing 60 histologically proven NMSCs were enrolled and treated with the Rhenium-SCT\u00ae between October 2017 and January 2020. Lesions were located on the face, ears, nose or scalp (<jats:italic>n<\/jats:italic>\u2009=\u200946), extremities (<jats:italic>n<\/jats:italic>\u2009=\u20099), and trunk (<jats:italic>n<\/jats:italic>\u2009=\u20095). Mean surface areas were 7.0\u00a0cm<jats:sup>2<\/jats:sup> (1\u201336\u00a0cm<jats:sup>2<\/jats:sup>), mean thickness invasion was 1.1\u00a0mm (0.2\u20132.5\u00a0mm), and mean treatment time was 79\u00a0min (21\u201385\u00a0min). Superficial, mean, and target absorbed dose were 185\u00a0Gy, 63\u00a0Gy, and 31\u00a0Gy respectively. Patients were followed-up at 14, 30, 60, 90, and 180\u00a0days posttreatment, when dermoscopy and biopsy were performed. Mean follow-up was 20\u00a0months (range 3\u201333\u00a0months). Early skin toxicity was classified according to Common Terminology Criteria for Adverse Events (CTCAE). Cosmetic results were evaluated after at least 12\u00a0months according to Radiation Therapy Oncology Group (RTOG) scale.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>At 6\u00a0months follow-up, histology and dermoscopy were available for 54\/60 lesions, of which 53\/54 (98%) completely responded. One patient showed a 1-cm<jats:sup>2<\/jats:sup> residual lesion that was subsequently surgically excised. Twelve months after treatment, 41\/41 evaluable lesions were free from relapse. Twenty four months after treatment, 23\/24 evaluable lesions were free of relapse. In 56\/60 lesions early side effects, resolving within 32\u00a0days were classified as grades 1\u20132 (CTCAE). In the remaining 4\/60 lesions, these findings were classified as grade 3 (CTCAE) and lasted up to 8\u201312\u00a0weeks but all resolved within 90\u00a0days. After at least 12\u00a0months (12\u201333\u00a0months), cosmetic results were excellent (30 lesions) or good (11 lesions).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>High dose brachytherapy with Rhenium-SCT\u00ae is a noninvasive, reasonably safe, easy to perform, effective and well-tolerated approach to treat NMSCs, and it seems to be a useful alternative option when surgery or radiation therapy are difficult to perform or not recommended. In our population 98% of the treated lesions resolved completely after a single application and only one relapsed after 2\u00a0years. Larger patients\u2019 population and longer follow-up are needed to confirm these preliminary data and to find the optimal dose to administer in order to achieve complete response without significant side effects.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00259-020-05088-z","type":"journal-article","created":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T23:02:35Z","timestamp":1604358155000},"page":"1511-1521","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["High dose brachytherapy with non sealed 188Re (rhenium) resin in patients with non-melanoma skin cancers (NMSCs): single center preliminary results."],"prefix":"10.1007","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9215-7579","authenticated-orcid":false,"given":"Paolo","family":"Castellucci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Savoia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Farina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. M.","family":"Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Patrizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Baraldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Zagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Vichi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Pettinato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. G.","family":"Morganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Strigari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Fanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,2]]},"reference":[{"key":"5088_CR1","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1001\/jamadermatol.2015.1187","volume":"151","author":"HW Rogers","year":"2015","unstructured":"Rogers HW, Weinstock MA, Feldman SR, Coldiron BM. Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the U.S. population, 2012. JAMA Dermatol. 2015;151:1081\u20136.","journal-title":"JAMA Dermatol"},{"key":"5088_CR2","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.1016\/j.ejca.2014.08.018","volume":"50","author":"E van Loo","year":"2014","unstructured":"van Loo E, Mosterd K, Krekels GA, et al. Surgical excision versus Mohs\u2019 micrographic surgery for basal cell carcinomaof the face: a randomised clinical trial with 10 year followup. Eur J Cancer. 2014;50:3011\u201320.","journal-title":"Eur J Cancer"},{"key":"5088_CR3","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1097\/DSS.0000000000000478","volume":"41","author":"AN Kauvar","year":"2015","unstructured":"Kauvar AN, Arpey CJ, Hruza G, et al. Consensus for nonmelanoma skin cancer treatment, part II: squamous cell carcinoma, including a cost analysis of treatment methods. Dermatol Surg. 2015;41:1214\u201340.","journal-title":"Dermatol Surg"},{"issue":"2","key":"5088_CR4","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jaad.2017.08.059","volume":"78","author":"SKT Que","year":"2018","unstructured":"Que SKT, Zwald FO, Schmults CD. Cutaneous squamous cell carcinoma: incidence, risk factors, diagnosis, and staging. J Am Acad Dermatol. 2018;78(2):237\u201347.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"5088_CR5","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1080\/09546634.2017.1341617","volume":"29","author":"K Ota","year":"2018","unstructured":"Ota K, Adar T, Dover L, Khachemoune AJ. Review: the reemergence of brachytherapy as treatment for non-melanoma skin cancer. Dermatol Treat. 2018;29(2):170\u20135. https:\/\/doi.org\/10.1080\/09546634.2017.1341617.","journal-title":"Dermatol Treat"},{"issue":"6","key":"5088_CR6","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/j.brachy.2015.06.005","volume":"14","author":"Z Ouhib","year":"2015","unstructured":"Ouhib Z, Kasper M, Perez Calatayud J, Rodriguez S, Bhatnagar A, Pai S, et al. Aspects of dosimetry and clinical practice of skin brachytherapy: The American Brachytherapy Society working group report. Brachytherapy. 2015;14(6):840\u201358.","journal-title":"Brachytherapy"},{"issue":"6","key":"5088_CR7","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1111\/j.1365-2230.2008.02852.x","volume":"33","author":"AF Sedda","year":"2008","unstructured":"Sedda AF, Rossi G, Cipriani C, Carrozzo AM, Donati P. Dermatological high-dose-rate brachytherapy for the treatment of basal and squamous cell carcinoma. Clin Exp Dermatol. 2008;33(6):745\u20139.","journal-title":"Clin Exp Dermatol"},{"issue":"2","key":"5088_CR8","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1684\/ejd.2013.1927","volume":"23","author":"AM Carrozzo","year":"2013","unstructured":"Carrozzo AM, Sedda AF, Muscardin L, Donati P, Cipriani C. Dermo beta brachytherapy with188-Re in squamous cell carcinoma of the penis: a new therapy. Eur J Dermatol. 2013;23(2):183\u20138.","journal-title":"Eur J Dermatol"},{"key":"5088_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/09546634.2020.1793890","volume":"22","author":"C Cipriani","year":"2020","unstructured":"Cipriani C, Desantis M, Dahlhoff G, et al. Personalized irradiation therapy for NMSC by rhenium-188 skin cancer therapy: a long-term retrospective study. J Dermatolog Treat. 2020;22:1\u20137. https:\/\/doi.org\/10.1080\/09546634.2020.1793890.","journal-title":"J Dermatolog Treat"},{"key":"5088_CR10","doi-asserted-by":"publisher","unstructured":"Cipriani C, Sedda AF. Epidermal radionuclide therapy - dermatological high-dose-rate brachytherapy for the treatment of basal and squamous cell carcinoma. Therapeutic Nuclear Medicine, Springer-Verlag Berlin-Heidelberg; 2012 https:\/\/doi.org\/10.1007\/174_2012_669.","DOI":"10.1007\/174_2012_669"},{"key":"5088_CR11","unstructured":"US National Cancer Institute (NCI).Common terminology criteria for adverse Eventes 5.0 Published November 27th 2017."},{"key":"5088_CR12","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/0360-3016(95)00060-C","volume":"31","author":"JD Cox","year":"1995","unstructured":"Cox JD, Stetz J, Pajak TF. Toxicity criteria of the radiation therapy oncology group (RTOG) and the European organization for research and treatment of cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31:1341\u20136.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"5088_CR13","volume-title":"VARSKIN 5: A computer code for skin contaminationDosimetry. NUREG\/CR-6918, Rev. 2","author":"DM Hamby","year":"2014","unstructured":"Hamby DM, Mangini CD, Caffrey JA, Tang M. VARSKIN 5: A computer code for skin contaminationDosimetry. NUREG\/CR-6918, Rev. 2. Washington, DC: U.S. Nuclear Regulatory Commission; 2014."},{"key":"5088_CR14","doi-asserted-by":"crossref","unstructured":"Ferrari A, Sala PR, Fasso A, Ranft J. FLUKA: a multi-particle transport code. CERN 2005-10 (2005), INFN\/TC 05\/11, SLAC-R-773.2005.","DOI":"10.2172\/877507"},{"key":"5088_CR15","doi-asserted-by":"publisher","first-page":"837","DOI":"10.2307\/2531595","volume":"44","author":"ER DeLong","year":"1988","unstructured":"DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44:837\u201345.","journal-title":"Biometrics"},{"key":"5088_CR16","unstructured":"R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for statistical computing; 2020. URL https:\/\/www.r-project.org\/.\u00a0Accessed 18 July 2020."},{"issue":"8","key":"5088_CR17","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1080\/09546634.2019.1573310","volume":"30","author":"A Pashazadeh","year":"2019","unstructured":"Pashazadeh A, Boese A, Friebe M. Radiation therapy techniques in the treatment of skin cancer: an overview of the current status and outlook. J Dermatolog Treat. 2019;30(8):831\u20139. https:\/\/doi.org\/10.1080\/09546634.2019.1573310.","journal-title":"J Dermatolog Treat"},{"issue":"3","key":"5088_CR18","doi-asserted-by":"publisher","first-page":"251","DOI":"10.5114\/jcb.2017.68191","volume":"9","author":"R Ballester-S\u00e1nchez","year":"2017","unstructured":"Ballester-S\u00e1nchez R, Pons-Llanas O, Candela-Juan C, et al. Two years results of electronic brachytherapy for basal cell carcinoma. J Contemp Brachytherapy. 2017;9(3):251\u20135. https:\/\/doi.org\/10.5114\/jcb.2017.68191.","journal-title":"J Contemp Brachytherapy"},{"issue":"3","key":"5088_CR19","doi-asserted-by":"publisher","first-page":"231","DOI":"10.5114\/jcb.2015.52140","volume":"7","author":"R Ballester-S\u00e1nchez","year":"2015","unstructured":"Ballester-S\u00e1nchez R, Pons-Llanas O, Candela-Juan C, et al. Efficacy and safety of electronic brachytherapy for superficial and nodular basal cell carcinoma. J Contemp Brachytherapy. 2015;7(3):231\u20138. https:\/\/doi.org\/10.5114\/jcb.2015.52140.","journal-title":"J Contemp Brachytherapy"}],"updated-by":[{"DOI":"10.1007\/s00259-021-05363-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,4,19]],"date-time":"2021-04-19T00:00:00Z","timestamp":1618790400000}}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-020-05088-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-020-05088-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-020-05088-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T20:09:51Z","timestamp":1627675791000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-020-05088-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,2]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["5088"],"URL":"https:\/\/doi.org\/10.1007\/s00259-020-05088-z","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00259-021-05363-7","asserted-by":"object"}]},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,2]]},"assertion":[{"value":"17 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00259-021-05363-7","URL":"https:\/\/doi.org\/10.1007\/s00259-021-05363-7","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Local Ethical Committee (23\/2019\/Oss\/AOUBo).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Patients have signed written informed consent to participate.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}